乳がんリキッドバイオプシー検査機器市場- 世界の産業規模、シェア、動向、機会、予測、提供品目別、循環バイオマーカー別、用途別、地域別、競合別、2020年～2030F

乳がんリキッドバイオプシー検査機器の世界市場は、2024年に8億3,536万米ドルと評価され、2030年までのCAGRは17.20%で、予測期間中に目覚ましい成長を予測しています。

リキッドバイオプシーは、乳がんの診断と治療の領域で貴重な資産としての役割を果たします。リキッドバイオプシーによる変異の解析は、腫瘍特有の遺伝子変化に基づいて個々の患者に合わせた標的治療の同定を助ける。例えば、転移性乳がん患者の場合、HR陽性腫瘍の約40％に見られるPIK3CA変異のスクリーニングは、最も効果的な治療法の決定に役立ちます。例えば、米国がん学会（ASC）レポート2023によると、乳がんは皮膚がんを除いて米国で女性に最も多いがんです。毎年診断される全女性がんの30％を占めています。乳がんの有病率と死亡率を下げるため、政府は診断と治療にかかる費用を患者支援する政策を実施し、法律を導入しています。また、世界保健機関（WHO）の2023年版報告書によると、乳がんは年間230万人以上の患者が診断されており、成人の間で最も罹患率の高いがんとなっています。しかし、乳がん関連死亡の約80%は低・中所得国で発生しています。

市場促進要因

がん検出技術の進歩

主な市場課題

限られた感度と特異度

主な市場動向

従来の診断法との統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の乳がんリキッドバイオプシー検査機器市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 提供品目別（アッセイおよび試薬キット、機器）
  • 循環バイオマーカー（循環腫瘍DNA、循環腫瘍細胞、細胞外小胞）
  • 用途別（がん用途、非がん用途）
  • 地域別
  • 企業別（2022）
• 製品市場マップ
  • 提供別
  • 循環バイオマーカー別
  • 用途別
  • 地域別

第6章 北米の乳がんリキッドバイオプシー検査機器市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の乳がんリキッドバイオプシー検査機器市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋地域の乳がんリキッドバイオプシー検査機器市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国

第9章 南米の乳がんリキッドバイオプシー検査機器市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの乳がんリキッドバイオプシー検査機器市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• A Menarini AG
• NeoGenomics Laboratories Inc
• F Hoffmann-La Roche AG
• Myriad Genetics Inc
• QIAGEN NV
• Biocept Inc
• Sysmex Corp
• Fluxion Biosciences Inc
• Thermo Fisher Scientific Inc
• Epic Sciences Inc

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Breast Cancer Liquid Biopsy Testing Devices Market was valued at USD 835.36 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 17.20% through 2030. Liquid biopsy serves as a valuable asset in the realm of breast cancer diagnosis and treatment. The analysis of mutations through liquid biopsy aids in the identification of targeted therapies tailored to individual patients based on their tumor-specific genetic alterations. To illustrate, in the case of patients grappling with metastatic breast cancer, screening for the PIK3CA mutation, which is found in around 40% of HR-positive tumors, assists in determining the most effective treatment path. For instance, according to the American Society of Cancer (ASC) Report 2023, breast cancer remains the most common cancer among women in the United States, excluding skin cancers. It accounts for 30% of all female cancers diagnosed annually. In an effort to reduce the prevalence and mortality rates of breast cancer, the government has implemented policies and introduced laws to support patients with the costs of diagnosis and treatment. Also, according to the World Health Organization 2023 report, more than 2.3 million cases of breast cancer are diagnosed annually, making it the most prevalent cancer among adults. However, approximately 80% of breast cancer-related deaths occur in low- and middle-income countries.

Key Market Drivers

Advancements in Cancer Detection Technology

The landscape of cancer detection and diagnosis is evolving rapidly, and one area of remarkable progress is the development of liquid biopsy testing devices. These devices, which have gained prominence in the healthcare industry, are offering a non-invasive, highly sensitive, and patient-friendly approach to detect and monitor cancer, with breast cancer being a significant focus.

One of the keyways advancements in cancer detection technology are boosting the growth of the global breast cancer liquid biopsy market is by enhancing sensitivity and specificity. Liquid biopsies can now detect minute traces of circulating tumor DNA (ctDNA) or other biomarkers in a patient's bloodstream. This increased sensitivity ensures that even small tumors or minimal residual disease (MRD) can be detected accurately, which was often challenging with traditional diagnostic methods.

Key Market Challenges

Limited Sensitivity and Specificity

While liquid biopsy testing devices have advanced considerably, they may still face challenges related to sensitivity and specificity. Detecting circulating tumor DNA (ctDNA) or other biomarkers in the bloodstream can be challenging, especially for small or early-stage tumors. Improving the sensitivity and specificity of these tests remains a priority for the industry.

Key Market Trends

Integration with Conventional Diagnostics

The trend is moving towards the integration of liquid biopsy testing devices with traditional diagnostic methods. Combining liquid biopsies with imaging and tissue biopsies can provide a more comprehensive understanding of the disease. This integrated approach offers greater diagnostic accuracy and opens up new avenues for treatment decisions.

Key Market Players

• A Menarini AG
• NeoGenomics Laboratories Inc
• F Hoffmann-La Roche AG
• Myriad Genetics Inc
• QIAGEN NV
• Biocept Inc
• Sysmex Corp
• Fluxion Biosciences Inc
• Thermo Fisher Scientific Inc
• Epic Sciences Inc

Report Scope:

In this report, the Global Breast Cancer Liquid Biopsy Testing Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Breast Cancer Liquid Biopsy Testing Devices Market, By Offerings:

• Assay & Reagents Kits
• Instruments

Breast Cancer Liquid Biopsy Testing Devices Market, By Circulating Biomarker:

• Circulating Tumor DNA
• Circulating Tumor Cell
• Extracellular Vesicles

Breast Cancer Liquid Biopsy Testing Devices Market, By Application:

• Cancer Applications
• Non-Cancer Applications

Breast Cancer Liquid Biopsy Testing Devices Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Breast Cancer Liquid Biopsy Testing Devices Market.

Available Customizations:

Global Breast Cancer Liquid Biopsy Testing Devices market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 5.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 5.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Offerings
  • 5.3.2. By Circulating Biomarker
  • 5.3.3. By Application
  • 5.3.4. By Region

6. North America Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 6.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 6.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Offerings
      • 6.3.1.2.2. By Circulating Biomarker
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Offerings
      • 6.3.2.2.2. By Circulating Biomarker
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Offerings
      • 6.3.3.2.2. By Circulating Biomarker
      • 6.3.3.2.3. By Application

7. Europe Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 7.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 7.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Offerings
      • 7.3.1.2.2. By Circulating Biomarker
      • 7.3.1.2.3. By Application
  • 7.3.2. United Kingdom Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Offerings
      • 7.3.2.2.2. By Circulating Biomarker
      • 7.3.2.2.3. By Application
  • 7.3.3. France Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Offerings
      • 7.3.3.2.2. By Circulating Biomarker
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Offerings
      • 7.3.4.2.2. By Circulating Biomarker
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Offerings
      • 7.3.5.2.2. By Circulating Biomarker
      • 7.3.5.2.3. By Application

8. Asia-Pacific Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 8.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 8.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Offerings
      • 8.3.1.2.2. By Circulating Biomarker
      • 8.3.1.2.3. By Application
  • 8.3.2. Japan Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Offerings
      • 8.3.2.2.2. By Circulating Biomarker
      • 8.3.2.2.3. By Application
  • 8.3.3. India Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Offerings
      • 8.3.3.2.2. By Circulating Biomarker
      • 8.3.3.2.3. By Application
  • 8.3.4. Australia Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Offerings
      • 8.3.4.2.2. By Circulating Biomarker
      • 8.3.4.2.3. By Application
  • 8.3.5. South Korea Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Offerings
      • 8.3.5.2.2. By Circulating Biomarker
      • 8.3.5.2.3. By Application

9. South America Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 9.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 9.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Offerings
      • 9.3.1.2.2. By Circulating Biomarker
      • 9.3.1.2.3. By Application
  • 9.3.2. Argentina Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Offerings
      • 9.3.2.2.2. By Circulating Biomarker
      • 9.3.2.2.3. By Application
  • 9.3.3. Colombia Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Offerings
      • 9.3.3.2.2. By Circulating Biomarker
      • 9.3.3.2.3. By Application

10. Middle East and Africa Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 10.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 10.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Offerings
      • 10.3.1.2.2. By Circulating Biomarker
      • 10.3.1.2.3. By Application
  • 10.3.2. Saudi Arabia Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Offerings
      • 10.3.2.2.2. By Circulating Biomarker
      • 10.3.2.2.3. By Application
  • 10.3.3. UAE Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Offerings
      • 10.3.3.2.2. By Circulating Biomarker
      • 10.3.3.2.3. By Application
  • 10.3.4. Kuwait Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Offerings
      • 10.3.4.2.2. By Circulating Biomarker
      • 10.3.4.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. A Menarini AG
• 14.2. NeoGenomics Laboratories Inc
• 14.3. F Hoffmann-La Roche AG
• 14.4. Myriad Genetics Inc
• 14.5. QIAGEN NV
• 14.6. Biocept Inc
• 14.7. Sysmex Corp
• 14.8. Fluxion Biosciences Inc
• 14.9. Thermo Fisher Scientific Inc
• 14.10. Epic Sciences Inc

15. Strategic Recommendations

16. About Us & Disclaimer